Filing Flows › Health Care › Caribou Biosciences (CRBU)
Caribou Biosciences (CRBU) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · Caribou Biosciences (CRBU) Q3 2026 earnings results →
Q3 2026 Revenue down 27% year over year to $1.6M
Caribou Biosciences made $1.6M in Q3 2026 (-27% Y/Y). Operating margin n/m, net loss $26.6M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.6M in Q3 2026, down 27% year over year and up 7% from the previous quarter.
Operating costs exceeded revenue by $27.6M, an operating margin of -1720.1%. Total costs fell 7% while revenue fell 27%. The quarter ended with a net loss of $26.6M, wider than the previous quarter's $24.3M loss.
Operating cash flow was −$22.5M. Non-cash charges added back $590K of depreciation and amortization and $2.2M of share-based compensation. Working capital and other items added $1.3M. Capital expenditures of $19K exceeded it, leaving free cash flow of −$22.5M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 5, 2026 | $1.6M | -27% | n/m | −$26.6M | −$22.5M |
| Q2 2026 | 10-Q | Aug 13, 2026 | $1.5M | -44% | n/m | −$24.3M | −$22.8M |
| Q1 2026 | 10-Q | May 7, 2026 | $2.4M | +2% | n/m | −$25.1M | −$27.0M |
| Q4 2025 | 10-K | Mar 5, 2026 | $3.9M | +90% | -722.0% | −$26.5M | −$20.8M |
| Q3 2025 | 10-Q | Nov 12, 2025 | $2.2M | +9% | n/m | −$27.5M | −$25.2M |
| Q2 2025 | 10-Q | Aug 12, 2025 | $2.7M | -23% | n/m | −$54.1M | −$28.3M |
| Q1 2025 | 10-Q | May 8, 2025 | $2.4M | -3% | n/m | −$40.0M | −$36.7M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Caribou Biosciences
We are a clinical-stage C lustered R egularly I nterspaced S hort P alindromic R epeats (“CRISPR”) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Our genome-editing platform is based on our novel chRDNA ( C RISPR h ybrid R NA- DNA , or “chRDNA,” pronounced “chardonnay”) genome-editing technology, which enables more precise genome editing of allogeneic cell therapies. Our allogeneic, or off-the-shelf, chimeric antigen receptor (“CAR”) -T (“CAR-T”) cell therapy product candidates are manufactured in advance with cells from healthy donors, with the goal of enabling broad patient access, rapid patient treatment, and increased manufacturing scale.
In its own words, from its 10-K, filed Mar 5, 2026.
Caribou Biosciences against its Biological Products, (No Diagnostic Substances) peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -27% against the peers' median +11%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| CRBU Caribou Biosciences | Q3 2026 | $1.6M | -27% | n/m |
| AMGN Amgen | Q3 2026 | $10.4B | +8% | 35.8% |
| GILD Gilead Sciences | Q3 2026 | $8.3B | +7% | 41.7% |
| BIIB Biogen | Q3 2026 | $2.8B | +11% | -0.3% |
| MRNA Moderna | Q3 2026 | $1.3B | +29% | 9.9% |
| NBIX Neurocrine Biosciences | Q3 2026 | $1.1B | +41% | 29.5% |
| EXEL Exelixis | Q3 2026 | $659M | +10% | 40.8% |
| HALO Halozyme Therapeutics | Q3 2026 | $493M | +39% | 59.8% |
| MGTX MeiraGTx Holdings | Q2 2026 | $321M | 87× | 76.0% |
Source: Caribou Biosciences 10-Q on SEC EDGAR · CIK 1619856 · Biological Products, (No Diagnostic Substances)
Guidance and outlook
13F: who owns CRBU and who is buying
More on CRBU
- How Caribou Biosciences makes money: revenue by segment
- Caribou Biosciences next earnings date and what analysts expect
- Caribou Biosciences stock forecast, price target and fair value
- Who owns Caribou Biosciences stock: holders, funds and Congress trades
- Caribou Biosciences guidance and outlook
- Caribou Biosciences recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results